{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:03:34Z","timestamp":1790352214382,"version":"4.1.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background\/Aim<\/jats:title><jats:p>Telitacicept has shown promise in disease control of systemic lupus erythematosus (SLE). This study aimed to evaluate the impact of telitacicept on gonadal function in adult female patients with SLE.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this prospective cohort study, adult female SLE patients aged 18 to 45 years were included and divided into telitacicept and non-telitacicept group. Hormonal levels of estradiol (E2), follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin (PRL), and anti-M\u00fcllerian hormone (AMH) were measured at baseline, month 1, 3, and 6 post-treatment. Generalized estimating equations adjusting for baseline confounders was used.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 78 patients were included, with 38 in the telitacicept group and 40 in the non-telitacicept group. Telitacicept significantly decreased PRL and LH levels (both adjusted P<jats:sub>time<\/jats:sub>&amp;lt;0.001), with greater reduction compared to non-telitacicept treatment (adjusted P<jats:sub>group<\/jats:sub>=0.001 and &amp;lt;0.001, respectively). In the multivariate logistic regression, telitacicept treatment was associated with a significantly lower incidence of abnormal PRL levels at month 6 (odds ratio=0.138, 95% confidence interval: 0.036-0.527, P = 0.004). The levels of AMH and E2 were increased and the levels of FSH were decreased (all adjusted P<jats:sub>time<\/jats:sub>&amp;lt;0.05), while the changes of AMH, E2 and FSH levels were similar between the two groups (all adjusted P<jats:sub>group<\/jats:sub>&amp;gt;0.05). SLE Disease Activity Index scores were significantly lower with telitacicept compared to non-telitacicept treatment at month 1, 3 and 6 post-treatment (all P&amp;lt;0.05). The incidence of adverse events was similar between the two groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Telitacicept demonstrates significant benefits in improving gonadal function and controlling disease activity in female SLE patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1610136","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:31:35Z","timestamp":1759210295000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of telitacicept on gonadal function in adult female patients with systemic lupus erythematosus: a prospective cohort study"],"prefix":"10.3389","volume":"16","author":[{"given":"Ziyan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianni","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yabin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000480","article-title":"Epidemiology of systemic lupus erythematosus: an update","volume":"30","author":"Stojan","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00668-1","article-title":"Global epidemiology of systemic lupus erythematosus","volume":"17","author":"Barber","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.bpobgyn.2019.09.002","article-title":"Pregnancy and systemic lupus erythematosus","volume":"64","author":"Petri","year":"2020","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00398-2","article-title":"Systemic lupus erythematosus","volume":"403","author":"Hoi","year":"2024","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"998","DOI":"10.3390\/jcm10050998","article-title":"High comorbidity burden in patients with SLE: data from the community-based lupus registry of crete","volume":"10","author":"Gergianaki","year":"2021","journal-title":"J Clin Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","article-title":"Update omicronn the diagnosis and management of systemic lupus erythematosus","volume":"80","author":"Fanouriakis","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.18502\/jfrh.v15i1.6076","article-title":"Evaluation of the ovarian reserve in women with systemic lupus erythematosus","volume":"15","author":"Morales-Martinez","year":"2021","journal-title":"J Family Reprod Health"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1132045","article-title":"A new insight into the impact of systemic lupus erythematosus on oocyte and embryo development as well as female fertility","volume":"14","author":"Mao","year":"2023","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"103038","DOI":"10.1016\/j.autrev.2022.103038","article-title":"Factors associated with fertility abnormalities in women with systemic lupus erythematosus: a systematic review and meta-analysis","volume":"21","author":"Giambalvo","year":"2022","journal-title":"Autoimmun Rev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-018-1783-1","article-title":"Anti-Mullerian hormone serum levels in systemic lupus erythematosus patients: Influence of the disease severity and therapy on the ovarian reserve","volume":"63","author":"Di Mario","year":"2019","journal-title":"Endocrine"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/art.40057","article-title":"Effect of corticosteroids and cyclophosphamide on sex hormone profiles in male patients with systemic lupus erythematosus or systemic sclerosis","volume":"69","author":"Arnaud","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e000439","DOI":"10.1136\/lupus-2020-000439","article-title":"Anti-Mullerian hormone in African-American women with systemic lupus erythematosus","volume":"7","author":"Angley","year":"2020","journal-title":"Lupus Sci Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/art.40079","article-title":"Brief report: the euro-lupus low-dose intravenous cyclophosphamide regimen does not impact the ovarian reserve, as measured by serum levels of anti-mullerian hormone","volume":"69","author":"Tamirou","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01591-1","article-title":"Telitacicept: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224854","article-title":"Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"83","author":"Wu","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2023-eular.1727","article-title":"OP0137 Efficacy and safety of telitacicept, a novel blys\/april dual inhibitor, in patients with systemic lupus erythematosus: a phase 3, randomized, placebo-controlled 52-week study","volume":"82","author":"Wang","year":"2023","journal-title":"Ann Rheumatic Diseases"},{"key":"B17","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s12884-024-06632-7","article-title":"Successful pregnancy in a patient with IgA nephropathy treated with telitacicept: a case report","volume":"24","author":"Du","year":"2024","journal-title":"BMC Pregnancy Childbirth"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209770","article-title":"EULAR recommendations for women\u2019s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and\/or antiphospholipid syndrome","volume":"76","author":"Andreoli","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902391","article-title":"Protective and pathogenic roles for B cells during systemic autoimmunity in NZB\/W F1 mice","volume":"184","author":"Haas","year":"2010","journal-title":"J Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/0961203308094652","article-title":"Menstrual and hormonal alterations in juvenile systemic lupus erythematosus","volume":"18","author":"Medeiros","year":"2009","journal-title":"Lupus"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.5114\/pm.2016.65666","article-title":"Autoimmune premature ovarian failure","volume":"15","author":"Komorowska","year":"2016","journal-title":"Prz Menopauzalny"},{"key":"B22","article-title":"Association between prolactin and disease activity in systemic lupus erythematosus. Influence of statistical power","volume":"26","author":"Blanco-Favela","year":"1999","journal-title":"J Rheumatol"},{"key":"B23","article-title":"Ovarian function and disease activity in patients with systemic lupus erythematosus","volume":"26","author":"Shabanova","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/OGX.0000000000000160","article-title":"Ovarian function and reproductive outcomes of female patients with systemic lupus erythematosus and the strategies to preserve their fertility","volume":"70","author":"Oktem","year":"2015","journal-title":"Obstet Gynecol Surv"},{"key":"B25","doi-asserted-by":"publisher","first-page":"105728","DOI":"10.1016\/j.jbspin.2024.105728","article-title":"Effect of systemic lupus erythematosus on the ovarian reserve: A systematic review and meta-analysis","volume":"91","author":"Han","year":"2024","journal-title":"Joint Bone Spine"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.21037\/apm.2020.02.11","article-title":"Assessment of ovarian reserve by serum anti-Mullerian hormone in patients with systemic lupus erythematosus: a meta-analysis","volume":"9","author":"Luo","year":"2020","journal-title":"Ann Palliat Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1177\/0961203312468624","article-title":"The impact of cyclophosphamide on menstruation and pregnancy in women with rheumatologic disease","volume":"22","author":"Harward","year":"2013","journal-title":"Lupus"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1017115","article-title":"Prolactin promotes proliferation of germinal center B cells, formation of plasma cells, and elevated levels of IgG3 anti-dsDNA autoantibodies","volume":"13","author":"Carreon-Talavera","year":"2022","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1016427","article-title":"The effect of prolactin on immune cell subsets involved in SLE pathogenesis","volume":"13","author":"Legorreta-Haquet","year":"2022","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1610136\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:31:36Z","timestamp":1759210296000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1610136\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2025.1610136"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1610136","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"article-number":"1610136"}}